Share

Biogen shares spike after FDA approves Alzheimer's drug

Biogen shares spiked in Monday's session after the FDA approved its controversial Alzheimer's drug, which is the first new therapy for the disease in nearly two decades. CNBC's Meg Tirrell reports.
02:48
Tue, Jun 8 20217:43 AM EDT